PT1268799E - Anticorpos antagonistas de ve-caderina sem efeitos adversos sobre a permeabilidade vascular - Google Patents

Anticorpos antagonistas de ve-caderina sem efeitos adversos sobre a permeabilidade vascular Download PDF

Info

Publication number
PT1268799E
PT1268799E PT01922997T PT01922997T PT1268799E PT 1268799 E PT1268799 E PT 1268799E PT 01922997 T PT01922997 T PT 01922997T PT 01922997 T PT01922997 T PT 01922997T PT 1268799 E PT1268799 E PT 1268799E
Authority
PT
Portugal
Prior art keywords
cadherin
human
antibody
adverse effects
vascular permeability
Prior art date
Application number
PT01922997T
Other languages
English (en)
Portuguese (pt)
Inventor
Fang Liao
Daniel J Hicklin
Peter Bohlen
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of PT1268799E publication Critical patent/PT1268799E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT01922997T 2000-03-31 2001-03-30 Anticorpos antagonistas de ve-caderina sem efeitos adversos sobre a permeabilidade vascular PT1268799E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54096700A 2000-03-31 2000-03-31

Publications (1)

Publication Number Publication Date
PT1268799E true PT1268799E (pt) 2009-05-11

Family

ID=24157649

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01922997T PT1268799E (pt) 2000-03-31 2001-03-30 Anticorpos antagonistas de ve-caderina sem efeitos adversos sobre a permeabilidade vascular

Country Status (12)

Country Link
US (4) US7371574B2 (https=)
EP (1) EP1268799B1 (https=)
JP (1) JP2003529370A (https=)
AT (1) ATE425255T1 (https=)
AU (1) AU2001249737A1 (https=)
CA (1) CA2404576A1 (https=)
CY (1) CY1109097T1 (https=)
DE (1) DE60137915D1 (https=)
DK (1) DK1268799T3 (https=)
ES (1) ES2323938T3 (https=)
PT (1) PT1268799E (https=)
WO (1) WO2001075109A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7481999B2 (en) 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
AU2003298475A1 (en) * 2002-11-14 2004-06-18 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
JP2004175689A (ja) * 2002-11-25 2004-06-24 Kureha Chem Ind Co Ltd 癌転移抑制剤
US20040167076A1 (en) * 2003-02-14 2004-08-26 Stamer W. Daniel Modulation of aqueous humor outflow by targeting vascular-endothelial-cadherin in schlemm's canal cells
GB0602063D0 (en) 2006-02-02 2006-03-15 Univ Manchester Cell Culture
US9207242B2 (en) * 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
WO2011071541A2 (en) * 2009-12-11 2011-06-16 The Scripps Research Institute Cadherin modulatory agents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5036003A (en) * 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
WO1993008210A1 (en) * 1991-10-18 1993-04-29 Beth Israel Hospital Association Vascular permeability factor targeted compounds
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
EP1306095A3 (en) * 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
EP0604603A4 (en) * 1992-04-17 1996-09-25 Doheny Eye Inst ELEMENTS AND METHODS FOR THE PRODUCTION OF CADHERINES.
US5597725A (en) * 1992-04-17 1997-01-28 Doheny Eye Institute Cadherin-specific antibodies and hybridoma cell lines
US5646250A (en) * 1992-04-17 1997-07-08 Doheny Eye Institute Cadherin polypeptides
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5730977A (en) * 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US20050222037A1 (en) * 1998-05-05 2005-10-06 Adherex Technologies, Inc. Compounds and methods for modulating VE-cadherin-mediated function
WO1999057149A2 (en) * 1998-05-05 1999-11-11 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US20030206902A1 (en) * 2001-03-05 2003-11-06 Fang Liao Ve-cadherin and vegfr-2 antagonists for therapeutic modulation of angiogenesis

Also Published As

Publication number Publication date
CY1109097T1 (el) 2014-07-02
DK1268799T3 (da) 2009-07-06
ATE425255T1 (de) 2009-03-15
AU2001249737A1 (en) 2001-10-15
DE60137915D1 (de) 2009-04-23
US7371574B2 (en) 2008-05-13
EP1268799B1 (en) 2009-03-11
US20020160003A1 (en) 2002-10-31
WO2001075109A3 (en) 2002-05-16
US20080317750A1 (en) 2008-12-25
EP1268799A2 (en) 2003-01-02
WO2001075109A2 (en) 2001-10-11
JP2003529370A (ja) 2003-10-07
CA2404576A1 (en) 2001-10-11
US20080311121A1 (en) 2008-12-18
US20090060909A1 (en) 2009-03-05
ES2323938T3 (es) 2009-07-28

Similar Documents

Publication Publication Date Title
CY1109097T1 (el) Ανταγωνιστες αντισωματων ve-καντερινης χωρις αρνητικες επιδρασεις επι αγγειακης διαπερατοτητας
IL126314A0 (en) Monoclonal specific antibodies
EP0344940A3 (en) Antibodies to human papillomavirus latent proteins, diagnostic systems and methods
DE69230545D1 (de) Antikörperderivate
EP1064303A4 (en) MONOCLONAL ANTIBODIES SPECIFIC TO THE EXTRACELLULAR DOMAIN OF THE PROSTATE SPECIFIC MEMBRANEANT
PH12021552002A1 (en) Anti-trem2 antibodies and methods of use thereof
DE69222303D1 (de) Kationisierte antikörper gegen intrazelluläre eiweisse
DK130791A (da) Monoklonale antistoffer, isaer for hb alc.
EP1285577A4 (en) CHIMERIC MOUSE HAVING IMMUNITY CREATED BY USE OF HUMAN CD34 POSITIVE CELLS AND USE THEREOF
DK0946873T3 (da) Fremgangsmåde til diagnose af allergisk bronkopulmonal aspergillose
WO2005103698A3 (en) Methods and antibodies for nitrofuran detection
DE69637909D1 (de) ANTI-Fas-LIGAND ANTIKÖRPER UND TESTMETHODE UNTER VERWENDUNG DERSELBEN
Beyers The detachment debate: The separation-adjustment link in adolescence.
AU4661293A (en) Peptides representing antigenic epitopes of ige present on b cell but not basophil surface
IL129236A0 (en) Monoclonal antibodies against a human act and serine protease complex
DE3785175D1 (de) A-assoziierte h-antigene, spezifische monoklonale antikoerper und methoden zu deren verwendung zur blutgruppenbestimmung.
IL96369A0 (en) Decapeptide,monoclonal antibodies directed thereto and their use in diagnosis
DK414386D0 (da) Monoklonalt antistof, cellelinje til fremstilling deraf og antistoffets anvendelse
AR023204A1 (es) Anticuerpos contra la proteina placentaria 13.
DK98692A (da) Monoklonalt antistof og fremgangsmaade til fremstilling deraf, hybridoma, som producerer det monoklonale antistof, og proeve for tumorcellefoelsomhed under anvendelse af det monoklonale antistof
ATE156711T1 (de) Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)
DE69111429D1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
WO2003061575A3 (en) Anti-idiotype antibody of disintegrin and uses thereof
ATE343596T1 (de) Humane monoklonale antikörper gegen inselzellantigen ia-2
UA109629C2 (uk) Людське моноклональне антитіло проти cd20